T20K / Cyxone - LARVOL DELTA

Cyxone receives Intention to Grant for European Unitary Patent for T20K [Google translation] (Cision) - "Cyxone...announce today that the company has received notice from the European Patent Office (EPO) that they intend to approve (Intention to Grant) a unitary patent for the sub-patent EP-Divisional Patent Application 18 172 126.7 with the title Cyclotides as immunosuppressive agents. The patent covers the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg. The European Patent Office announces that the patent application will be granted as a unitary patent from 1 November 2023 and will be valid in the states that have ratified the UPC (Unitary Patent Court) agreement - currently 17 of the 39 states that are members of the European Patent Office (EPO ) collaboration. The Intention to Grant communication is a formal notification from the patent office that indicates that the patent application has reached a level where the patent is about to be approved. Once approved, it will be valid until 2032."

Patent • CNS Disorders • Immunology • Multiple Sclerosis

Cyxone AB is carrying out a rights issue of shares for approximately SEK 36.3 million (Cision) - "The board of Cyxone AB...has today...decided to carry out a rights issue of a maximum of 213,296,902 shares for approximately SEK 36.3 million before issue costs (the 'Rights Issue'). In connection with the Rights Issue, the Company has received subscription obligations and guarantee commitments of approximately SEK 20 million from persons in the Company's management and board of directors as well as external investors corresponding to approximately 55 percent of the Rights Issue. The issue proceeds from the Rights Issue are primarily intended to be used to finance further clinical development for the programs with Rabeximod and T20K. Notice of the extraordinary general meeting will be published through a separate press release."

Financing • Acute Respiratory Distress Syndrome • CNS Disorders • Immunology • Multiple Sclerosis • Rheumatoid Arthritis

Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K (Market Screener) - "Cyxone...is pleased to announce that the European Patent Office has issued an intention to grant communication for EP-Divisional Patent Application 18 172 126.7....The application covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg. The intention to grant is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until 2032."

Patent • CNS Disorders • Immunology • Multiple Sclerosis

"BioStock: Cyxone rapporterar Q3 och presenterar T20K https://t.co/QXmt2RysTA" (@CisionNews)

"BioStock: Cyxone reports Q3 and presents T20K https://t.co/VZNLM9tuDg" (@CisionNews)

"Cyxone presents T20K program at the ECTRIMS conference https://t.co/dlONENvJrn" (@CisionNews)

"Cyxone presenterar T20K-programmet på ECTRIMS-konferensen https://t.co/DeHyKiAyLw" (@CisionNews)

"BioStock: Cyxone comments on scientific T20K article https://t.co/H5v39epxVp" (@CisionNews)

"BioStock: Cyxone kommenterar vetenskaplig T20K-artikel https://t.co/3Bh3rooVaF" (@CisionNews)

"Cyxone AB rapporterar lovande terapieffekt av T20K/KORa kombinationsbehandling i en terapeutisk preklinisk modell av MS https://t.co/IuDuBpxzUP" (@CisionNews)

"BioStock: Cyxone om framstegen i T20K-projektet https://t.co/YDTJlw7K9r" (@CisionNews)

"BioStock: Cyxone about the advancements in the T20K project https://t.co/VjSVB8t4hk" (@CisionNews)

"Cyxone meddelar lovande prekliniska resultat till stöd för en kombinationsbehandling med T20K vid multipel skleros https://t.co/Alh4Z2F8Pe" (@CisionNews)

"BioStock: Cyxone utforskar nya behandlingsalternativ för T20K https://t.co/3sUCSpIRTA" (@CisionNews)

"BioStock: Cyxone is exploring new treatment possibilities for T20K https://t.co/Io2S1p3zeN" (@CisionNews)

"Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K https://t.co/lljNJeDsoY" (@CisionNews)

Preclinical • CNS Disorders • Multiple Sclerosis